Pasar al contenido principal

REPRESION DEL SUPRESOR DE TUMORES FBP1 POR STARD1 Y SU IMPACTO EN LA PROGRESION DE MASH A HCC

PID2023-148803OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bile acids in liver and gastrointestinal cancer

  • Monte, Maria J.
  • Fàbrega, Laura
  • Romero, Marta R.
  • Temprano, Alvaro G.
  • Kaplowitz, Neil
  • García-Ruiz, Carmen
  • Marin, Jose J. G.
  • Fernández-Checa, José C.
Bile acids (BAs) are cholesterol-derived metabolites synthesized by hepatocytes and secreted in bile to follow an inter-organ transit to the intestine, where they facilitate fat digestion and the absorption of lipids and liposoluble vitamins. Traditionally considered mere end products of cholesterol catabolism, they are now acknowledged to play intricate roles in regulating intermediary metabolism by controlling the expression of crucial genes. Additionally, they exert a significant impact on inflammation, cytotoxicity, and carcinogenesis. Moreover, BAs have a critical impact on the crosstalk between gut microbiota and host physiology, which affects the progression of liver and gastrointestinal cancers. Clinical data and results from studies of animal models support the involvement of BAs in the development of hepatocellular carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, and pancreatic cancer. On the other hand, BAs and their derivatives have been proposed as pharmacological tools in strategies to restore abnormal hepatobiliary function and target cytostatic agents to cancers of the enterohepatic circuit. In the present review, we summarize basic concepts of BA physiology and regulation, as well as new advances in this expanding field of renewed interest for cancer biology, lending further support for the key role of BAs in liver and gastrointestinal cancer., We acknowledge the support from grants PID2019-111669RB-100, PID2020-115055RB-I00, PID2022-142956OB-100, PID2022-140210OB-100, PID2023-1488030B-100, 2024AEP053; 2023AEPP068 and 2020AEPP145 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI); Plan Nacional sobre Drogas grant 2024; and PI22/00526 from the Fondo de Investigaciones Sanitarias, Instituto Salud Carlos III, Spain co-funded by European Regional Development Fund/European Social Fund, Junta Castilla y Leon (SA113/P23) and from the CIBEREHD; as well as support from AGAUR of the Generalitat de Catalunya SGR-2021–00491, and funding from the European Horizon´s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679, as well as support from National Cancer Institute PO1 CA281819–01A1 from the NIH. L.F. is supported by a Jaume Bosch contract from the CIBEREHD, and she is a PhD student of the Biomedicine Program of the University of Barcelona, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Expression of SREBF2 and HMGCR discriminates the viability of steatotic grafts for human liver transplantation

  • Baulies, Anna
  • Torres, Sandra
  • Fucho, Raquel
  • Nuñez, Susana
  • Torres, Ferrán
  • Ferrer, Joana
  • Díaz, Alba
  • Rico, Naira
  • García-Valdecasas, Juan Carlos
  • Fuster, Josep
  • Adalia, Ramón
  • Paredes, David
  • Rimola, Antoni
  • Fernández-Checa, José C.
  • García-Ruiz, Carmen
We acknowledge the support from the grants Fundación Mutua Madrileña; grants PID2022-142956OB-100, PID2022-140169OB-C22 and PID2023-148803OB-100 from Plan Nacional de I + D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; as well as support from National Cancer Institute PO1 CA281819-01A1 from the NIH; AGAUR of the Generalitat de Catalunya SGR-2021-00491; ST holds a Ramón y Cajal fellowship (RYC2023-042649-I), and has received research support from the CIBEREHD intramural project 2023 (EHD25PI01). In addition, this project has received funding from the European Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

L‑Cysteine-Glutathione Mixed Disulfide, a Novel Bioavailable Sulfhydryl-Modified Glutathione Precursor, Protects against Early Liver Injury Induced by Short-Term Hypercholesterolemia

  • Martínez-Gili, Laura
  • Fucho, Raquel
  • Caballero, Francisco
  • Nuñez, Susana
  • Jaara, Hala Saeed
  • Alarcón-Vila, Cristina
  • Rico, Naira
  • Nagasawa, Herbert T.
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Torres, Sandra
Oxidative stress contributes to the damage of biological molecules and is linked to the development of multiple diseases, including liver disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD). In mammals, reduced glutathione (GSH) is a pivotal antioxidant that regulates cellular responses to redox imbalances caused by reactive oxygen and nitrogen species. The presence of reduced GSH within mitochondria is especially crucial for preserving the organelle’s routine performance by eliminating hydrogen peroxide generated under both physiological and pathological conditions. Cumulative evidence indicates that MASLD is associated with a diminished mitochondrial GSH (mGSH) pool, attributed to alterations in mitochondrial membrane fluidity due to cholesterol accumulation. Therefore, strategies aimed at boosting mGSH may offer therapeutic benefits against MASLD-associated liver injury. This study aims to investigate whether l-cysteine-glutathione disulfide (l-CySSG), a proposed GSH donor and precursor, can effectively restore total and mGSH in vitro and in vivo in mice fed cholesterol-enriched (HC) or methionine-choline-deficient (MCD) diets. Additionally, S-adenosylmethionine (SAM), a compound that serves as both a GSH precursor and a membrane fluidizer, along with N-acetylcysteine (NAC), a GSH precursor by providing cysteine, was used as the control molecules in the study. Our findings show that l-CySSG has great potential as a liver protector, especially due to its good oral bioavailability. Although it does not restore GSH levels in the mitochondria as efficiently as SAM does, l-CySSG can still offer protection against liver damage, possibly through mechanisms that are not yet fully understood. Overall, l-CySSG emerges as a promising alternative for treating conditions related to oxidative stress and mitochondrial dysfunction, paving the way for future research and therapeutic development., We are grateful for the support from grants PID2019- 111669RB-I00, PID2020-115055RB-I00, PID2022- 140169OB-C22 and PID2023-148803OB-100 from Plan Nacional de I+D funded by the Agencia Estatal de Investigacioń (AEI); Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; AGAUR of the Generalitat de Catalunya SGR-2021-00491; National Cancer Institute PO1 CA281819-01A1 from the NIH; 2024I076 from Government Delegation for the National Plan on Drugs (Ministry of Health). In addition, this project has received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679. ST holds a Ramoń y Cajal fellowship (RYC2023-042649-I), and has received research support from the CIBEREHD intramural project 2023 (EHD25PI01)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Cholesterol metabolic reprogramming in alcohol associated liver disease

  • Barrios, Mónica
  • Torres, Sandra
  • Fàbrega, Laura
  • Nuñez, Susana
  • Fucho, Raquel
  • Solsona-Vilarrasa, Estel
  • Rico, Naira
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
Trabajo presentado en el ASBMB Annual Meeting (2026), celebrado en Washington, D.C.(Estado Unidos), del 7 al 10 de marzo de 2026, We acknowledge the support from the grants PID2023-148803OB-I00, PID2022-142956OB-I00 and PID2022-140169OB-C22 from Plan Nacional de I+D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; as well as “Plan Nacional sobre Drogas” 2024 from the Ministry of Health, and support from AGAUR of the Generalitat de Catalunya SGR-2021-00491; CIBEREHD intramural project grant for junior researchers 2023; European Cooperation in Science & Technology (COST) ACTION CA17112 Prospective European Drug- Induced Liver Injury Network. National Cancer Institute PO1 CA281819-01A1 from the NIH; Beatriu de Pinós Post-doctoral grant (2021 BP00187); and from the European Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679. ST holds a Ramón y Cajal fellowship (RYC2023-042649-I)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prenols and prenoic acids in metabolism, disease, and aging

  • Verdaguer, Ignasi Bofill
  • Hernández, Agustín
  • Torres, Sandra
  • Rodríguez-Peiris, Maria
  • Arenas, Fabian
  • Martinez, Damelia Echevarria
  • López, Monica Barrios
  • Crispim, Marcell
  • Tabata, Yuki
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
Acyclic terpene derivatives are well-known as components of plant essential oils and insect hormones, yet their active biosynthesis also occurs in mammals. The terpenic alcohols-or prenols-geranylgeraniol (GGOH) and farnesol (FOH), together with their prenoic acids and derivatives, were identified in mammalian cells over 60 years ago but remain largely overlooked. These metabolites display diverse biological functions: they induce autophagy, inhibit tumor growth and inflammation, suppress cholesterol synthesis, enhance insulin sensitivity and cognition, regulate sexual characteristics, and promote healthy aging. In mammals, prenols arise from an age-dependent, bidirectional pathway that interconverts polyprenyl diphosphates, prenols, and prenoic acids. They can be oxidized into aldehydes and carboxylic acids or reconverted into diphosphate forms for use in protein prenylation and in the biosynthesis of ubiquinone, cholesterol, and dolichol. Although enzymes catalyzing polyprenyl diphosphate dephosphorylation and oxidation steps have been partly characterized, the kinases mediating their reverse phosphorylation remain unidentified. This review summarizes current advances in the understanding of prenol metabolism in mammals, emphasizing its role in metabolic regulation, disease prevention, and longevity. By integrating biochemical and physiological evidence, we highlight the emerging view that these small terpenes constitute a fundamental yet underexplored layer of metabolic control. Greater attention to this pathway may reveal novel strategies for maintaining metabolic health and mitigating age-related disorders., I. B. V. is fellow from the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); I. B. V. FAPESP process number: 2022/09526-4. M. C. was supported by a Beatriu de Pinós fellowship from AGAUR (Government of Catalonia). This work received support from the grants PID2022-142956OB-100, PID2022-140169OB-C22, and PID2023-148803OB-100 from Plan Nacional de I + D funded by the Agencia Estatal de Investigación (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER) and from the CIBEREHD; as well as support from National Cancer Institute PO1 CA281819-01A1 from the NIH, and from the European Horizon's research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement No 101095679. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health., Peer reviewed